Actively Recruiting
Evaluation of ROC-101 Oral Treatment with Standard Care in Adults with Pulmonary Arterial Hypertension and Interstitial Lung Disease-Associated Pulmonary Hypertension
Led by AllRock Bio, Inc. · Updated on 2026-10-08
40
Participants Needed
24
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effects of ROC-101 in adults diagnosed with Pulmonary Arterial Hypertension PAH or Pulmonary Hypertension associated with Interstitial Lung Disease ILD-PH. This Phase 2a, open-label, single-arm exploratory study includes participants classified under World Health Organization WHO Group I PAH or Group III ILD-PH, aiming to assess oral doses of ROC-101 alongside standard care. Participants will receive oral ROC-101 daily, starting at 10 mg and gradually increasing to 40 mg for a 24-week treatment period, combined with standard of care therapy. After this period, participants may continue in a long-term extension phase until the study program concludes or regulatory approval is granted. Evaluations include hemodynamic measurements obtained through right heart catheterization and monitoring of adverse events. Throughout the study, participants will undergo assessments such as pulmonary function tests, exercise capacity tests 6-minute walk distance, and right heart catheterization measurements at baseline and 24 weeks. Researchers will track changes in pulmonary vascular resistance and safety outcomes, along with various cardiac and respiratory function parameters. The total study duration includes the initial 24-week treatment phase followed by an optional long-term extension period for continued monitoring.
CONDITIONS
Brief Title
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here